Why Viridian Therapeutics Is One Of My 2023 Top Picks


  • Viridian was one of my top picks in 2022 and it made the 2023 list again.
  • VRDN-001 data continue to impress and Viridian looks well-positioned to disrupt the thyroid eye disease market later this decade.
  • The data point to VRDN-001 being at least faster acting than Tepezza and the 3mg/kg data suggest VRDN-003 could be dosed once a month as a subcutaneous injection.
  • The stock is still attractively valued despite the recent increase in valuation.
  • We're about to raise prices at my private investing ideas service, Growth Stock Forum, where members get access to portfolios, market alerts, real-time chat, and more. Learn More »
Choosing the key to success

BrianAJackson/iStock via Getty Images

Every year, I make a list of Top Picks which represents a narrowed-down version of our model portfolio. Viridian Therapeutics (NASDAQ:VRDN) was part of my Top Picks portfolio in 2022 and it made the 2023 list as well

I publish my best ideas and top coverage in the Growth Stock Forum. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up for a free trial to Growth Stock Forum. Join by February 9, to lock in the current rates before prices increase. To receive e-mail notifications for my public articles and blogs, please click the follow button.

This article was written by

ONeil Trader profile picture
Discovering growth and biotech stocks with significant upside potential
Former stockbroker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on growth and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection.

My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

Exclusive research: http://seekingalpha.com/author/oneil-trader/research

Disclosure: I/we have a beneficial long position in the shares of VRDN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.

Recommended For You

Comments (5)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.